{"slideshow_credits": null, "snippet": "Britain does not have as many takeover defenses as the United States, so it is puzzling why Pfizer did not make a full-fledged hostile bid for AstraZeneca.", "abstract": "Britain does not have as many takeover defenses as the United States, so it is puzzling why Pfizer did not make a full-fledged hostile bid for AstraZeneca.", "section_name": "Business Day", "print_page": null, "document_type": "blogpost", "byline": {"person": [{"firstname": "Steven", "role": "reported", "rank": 1, "organization": ""}], "original": "By STEVEN M. DAVIDOFF"}, "web_url": "http://dealbook.nytimes.com/2014/05/19/the-curious-incident-of-pfizers-final-offer-for-astrazeneca/", "lead_paragraph": null, "headline": {"main": "The Curious Incident of Pfizer's 'Final' Offer for AstraZeneca", "kicker": "DealBook"}, "_id": "537a2cef38f0d8768b063ab4", "word_count": "867", "multimedia": [{"height": 126, "url": "images/2014/05/20/business/dbpix-dealprof/dbpix-dealprof-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2014/05/20/business/dbpix-dealprof/dbpix-dealprof-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 600, "url": "images/2014/05/20/business/dbpix-dealprof/dbpix-dealprof-articleLarge.jpg", "legacy": {"xlarge": "images/2014/05/20/business/dbpix-dealprof/dbpix-dealprof-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "600"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2014/05/20/business/dbpix-dealprof/dbpix-dealprof-thumbStandard.jpg", "legacy": {"thumbnail": "images/2014/05/20/business/dbpix-dealprof/dbpix-dealprof-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2014-05-19T12:09:20Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "glocations", "value": "United States", "rank": "2"}, {"name": "glocations", "value": "Great Britain", "rank": "1"}, {"name": "organizations", "value": "Pfizer Inc", "rank": "2"}, {"name": "organizations", "value": "AstraZeneca PLC", "rank": "1"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": "3"}, {"name": "subject", "value": "Federal Taxes (US)", "rank": "2"}, {"name": "subject", "value": "Taxation", "rank": "4"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": "1"}], "blog": [], "subsection_name": "Dealbook", "type_of_material": "Blog"}